Humanigen

Humanigen ROA

Delisted

The Return on Assets (ROA) of Humanigen (HGENQ) as of Oct 5, 2026 is -631.52 %. In the previous year, Return on Assets (ROA) was -333.03 % — a change of 89.63% (lower).

ROA

-631.52 %

YoY

89.63%

Last updated:

In 2026, Humanigen's return on assets (ROA) was -631.52 %, a 89.63% increase from the -333.03 % ROA in the previous year.

The Humanigen ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2015
-317.31 USD
Jan 1, 2016
-572.46 USD
Jan 1, 2017
-1,316.77 USD
Jan 1, 2018
-875.91 USD
Jan 1, 2019
-1,978.85 USD
Jan 1, 2020
-131.10 USD
Jan 1, 2021
-333.03 USD
Jan 1, 2022
-631.52 USD
The Humanigen ROA history
YEARROAYoY
-631.52 %+89.63%
-333.03 %+154.03%
-131.10 %-93.38%
-1,978.85 %+125.92%
-875.91 %-33.48%
-1,316.77 %+130.02%
-572.46 %+80.41%
-317.31 %+258.89%
-88.41 %—
Access this data via the Eulerpool API

Humanigen Stock analysis

What does Humanigen do? Humanigen Inc is a pharmaceutical company specializing in the discovery, development, and marketing of drugs, therapies, and solutions in the field of medical research. The company was originally founded in 2000 and is headquartered in Burlingame, California. One major focus of Humanigen Inc is the treatment of severe and life-threatening diseases such as cancer or HIV/AIDS that have not been sufficiently addressed by other medications. The company has developed a range of special technologies that enable it to develop innovative and effective therapies and drugs. An important aspect of Humanigen Inc's business model is collaboration with other companies, institutions, and research facilities worldwide. Through partnerships and cooperation, the company is able to cover the entire spectrum of research and development, allowing it to develop treatment options even faster and more effectively. Humanigen Inc has several different divisions and products designed for various applications. An important subsidiary of the company is the Humanigen Center for HIV Cure Research, which specifically focuses on combating HIV. There, the company works closely with scientists, researchers, and partners to develop new and innovative treatment options. Another important product of Humanigen Inc is the drug Lenzilumab. Lenzilumab is an antibody used to treat severe and life-threatening diseases such as cancer and COVID-19. Lenzilumab has shown great promise in clinical trials and could be the key to developing new and effective treatment options. In addition, Humanigen Inc has filed a variety of patents that enable it to develop new and innovative technologies in medical research. Many of these technologies are also licensed by other companies and research institutions, promoting the growth and expansion of Humanigen Inc. In recent years, the company has also placed a major focus on the field of digital technology. By utilizing big data, artificial intelligence, and other digital technologies, Humanigen Inc is able to develop new therapy options even faster and more effectively, catering specifically to the needs of patients and doctors. Overall, Humanigen Inc is an innovative and rapidly growing company focused on the development of new and effective treatment options for serious diseases. Through collaboration with other companies and institutions, the development of new technologies, and a targeted focus on the needs of patients and doctors, the company is able to respond even faster and more effectively to challenges in the field of medical research. Humanigen is one of the most popular companies on Eulerpool.

ROA Details

Understanding Humanigen's Return on Assets (ROA)

Humanigen's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Humanigen's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Humanigen's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Humanigen’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Humanigen stock

Return on Assets (ROA) of Humanigen is -631.52 % in 2026.

Return on Assets (ROA) of Humanigen changed from -333.03 % to -631.52 %, representing a 89.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Humanigen since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Humanigen with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

Profitability — Humanigen

All Key Metrics — Humanigen